ERYTECH announces plans to conduct registered initial public offering in the United States Post author:admERY Post published:July 28, 2015 Post category:Newsroom ERYTECH today announced that the Company plans to conduct a registered initial public offering in the United States. You Might Also Like ERYTECH announces its financial calendar for 2014 January 20, 2014 ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia April 2, 2014 ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia August 29, 2016
ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia April 2, 2014
ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia August 29, 2016
